The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis

dc.contributor.authorKisli, Erol
dc.contributor.authorBaşer, M.
dc.contributor.authorAydın, Metin
dc.contributor.authorGüler, O.
dc.date.accessioned2021-06-23T19:20:42Z
dc.date.available2021-06-23T19:20:42Z
dc.date.issued2007
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground/Aims: To evaluate the effectiveness of a single administration of intravenous octreotide infusion in preventing post-ERCP pancreatitis and progressing hyperamylasemia. Methodology: One hundred and twenty (71 female, 59 male) patients who had been diagnosed with pancreaticobiliary pathology were included in this study. 100 microgram (0.1mg) octreotide diluted in 60mL normal saline solution administered intravenously 60 minutes prior to the procedure and continued during the procedure and after the procedure. Placebo was given in 87 patients. Patients were assessed clinically and serum amylase level was also measured before the procedure and 3, 12, and 24 hours after the procedure. We define clinical pancreatitis as serum amylase level greater than 4-5 times in conjunction with clinical assessment. Results: Hyperamylasemia was assessed in 14 of 33 (42.4%) administered octreotide patients. Clinical findings of pancreatitis were observed in 5 of these 14 (11.5%) patients. Hyperamylasemia was also assessed in 41 of 87 (47.1%) administered placebo patients. Clinical findings of pancreatitis were observed in 10 of these 41 (11.5) patients. There were no significant differences between the groups, statistically (p > 0.05) (Pearson chi-square test). Conclusions: The results of this trial indicate that a single administration of intravenous octreotide infusion does not prevent ERCP-induced pancreatitis and effect serum amylase level.en_US
dc.identifier.endpage253en_US
dc.identifier.issn0172-6390
dc.identifier.issue73en_US
dc.identifier.pmid17419271en_US
dc.identifier.scopus2-s2.0-34047114338en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage250en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/6155
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/17419271/
dc.identifier.volume54en_US
dc.identifier.wosWOS:000245252200053en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAydın, Metin
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPost-ERCP pancreatitisen_US
dc.subjectERCPen_US
dc.subjectOctreotideen_US
dc.titleThe role of octreotide versus placebo in the prevention of post-ERCP pancreatitisen_US
dc.typeArticleen_US

Dosyalar